Conference Coverage

VIDEO: Researchers closing in on the elusive ‘male pill’


 

REPORTING FROM ENDO 2018

Dimethandrolone, a modified form of testosterone, just might turn out to be the long-sought male contraceptive pill.

It blocks gonadotropin signaling and testosterone production in the testes. When capsules ranging in dose from 100 mg to 400 mg were given once daily to 100 men in a randomized, placebo controlled trial, the drop in testosterone was more than sufficient to block sperm production. Testosterone levels jumped back up to normal after the end of the 28-day trial, all without inducing liver toxicity or other serious problems.

“We are very excited [about] the results. It’s a big step forward in the development of the male pill. Our last great advance in male contraception was over 300 years ago with the development of the condom,” said senior investigator Stephanie Page, MD, PhD, head of the division of metabolism, endocrinology, and nutrition at the University of Washington, Seattle.

Pages

Recommended Reading

Meta-analysis shows correlation between diabetes and erectile dysfunction
MDedge Internal Medicine
Don’t omit extragenital gonorrhea, chlamydia testing
MDedge Internal Medicine
Nocturia linked to hypertension, diuretic use in community-based study of black men
MDedge Internal Medicine
Early births stress dads too
MDedge Internal Medicine
Ciprofloxacin cured gyrA wild-type Neisseria gonorrhoeae infections
MDedge Internal Medicine
From cells to socioeconomics, meth worsens HIV outcomes
MDedge Internal Medicine
Still too early to determine impact of 1-year deferral for MSM blood donors
MDedge Internal Medicine
Abstract: Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials
MDedge Internal Medicine
Free testosterone linked to frailty in older men
MDedge Internal Medicine
Without reliability, testosterone testing may fall short
MDedge Internal Medicine